S

Sanofi

Global pharma company; vaccines and R&D

Head of Global Ethics and Business Integrity Principles - Learning and Communications

Full-TimeUpdated on 10/23/2026Deadline 10/31/26
$210k - $303.3k
Expert
Bachelor's
Cambridge, MA, USA+1 moreMore locations: Morristown, NJ, USA
HybridHybrid role; workplace options are Morristown, NJ or Cambridge, MA.
Risk & ComplianceRegulatory Compliance & Ethics

About the job

Requirements
  • Proven experience leading global compliance principles and learning programs in healthcare, life sciences, or similarly highly regulated industries, with deep knowledge of bribery, corruption, conflicts of interest, fraud, and industry codes.
  • Demonstrated expertise in adult learning principles and instructional design, with hands-on experience managing learning management systems and using assessment analytics to improve training effectiveness and learning engagement for global audiences.
  • Familiarity with artificial intelligence tools and their application to compliance learning, including content generation, automation, and data-driven personalization.
  • Experience designing concise compliance principles, procedures, and guidance, with a proven track record of owning and evolving enterprise-wide compliance frameworks, including Codes of Conduct, global principles, and procedures.
  • Proven ability to collaborate across functions on sensitive processes such as conflicts of interest and to build cross-functional stakeholder communities in a global, matrixed organization.
  • Ability to lead and influence in a large, complex, global matrixed organization, with experience presenting to and advising senior executives.
  • A minimum of 10–12 years of experience in life sciences, pharmaceuticals, healthcare, or compliance, with significant experience managing global teams and programs.
  • A bachelor's degree is required.
Responsibilities
  • Evolve Sanofi's Code of Conduct and lead updates in partnership with senior leadership, ensuring it remains current, accessible, and culturally resonant across geographies, including global rollout communications and training.
  • Oversee mandatory Global Compliance Learning modules, including cross-functional strategy and coordination, governance, the non-completion process, coordination with People & Culture, exemption management, and confidential data sharing with appropriate safeguards.
  • Lead the design and deployment of global compliance learning programs grounded in adult learning principles, including needs analysis, instructional design, scenario-based content, microlearning, and effectiveness measurement; oversee strategic learning service providers, develop the annual Ethics & Business Integrity Learning Plan, and strategically distribute assignments, including a dedicated onboarding compliance learning track for new hires.
  • Drive the global Ethics & Business Integrity communications strategy and calendar, overseeing the design and delivery of proactive compliance communications that reinforce a culture of ethics and integrity.
  • Use artificial intelligence and advanced learning analytics to modernize and continuously improve a data-driven compliance learning ecosystem by enhancing content development, personalizing learning experiences, identifying knowledge gaps, targeting remediation, measuring training effectiveness, and demonstrating impact.
  • Support regional and local compliance teams with strategic guidance, tools, resources, and expertise to enable effective delivery of learning programs aligned with global standards.
  • Set the global strategy for Ethics & Business Integrity principles and Global Operating Procedures; oversee development, publication, and lifecycle management of key documents with Global Risk Owners and Global Process Owners; and support Global Risk Owners outside Ethics & Business Integrity in developing principles aligned with Sanofi's Code of Conduct.
  • Represent the compliance learning specialized segment within the Sanofi learning ecosystem by participating in the Enterprise Learning Advisory Board in alignment with the federated learning model.
  • Oversee global conflict-of-interest and disclosure programs, including integration of employees from newly acquired companies, streamlining disclosure cycles, and reconciliation processes.
  • Work with the Risk Management team and Global Risk Owners to align compliance learning priorities with enterprise risk assessments, gather learning needs, and ensure consistent engagement of Global Risk Owners throughout annual planning and content development.
  • Lead and develop a high-performing global team, fostering innovation, collaboration, and continuous improvement across regions.
Desired Qualifications
  • An advanced degree is preferred.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
  • June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
  • Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.

What critics are saying

  • Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
  • Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
  • Dupixent concentration makes 2030s patent loss an existential revenue shock.

What makes Sanofi unique

  • Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
  • October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
  • Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Professional Development Budget
  • Parental Leave

Company News

Associated Press
Oct 19th, 2026
Enable Injections wins first Japan approval for enFuse on-body injector via Sanofi's CirCLIQ

Enable Injections has won its first commercial product approval in Japan. The country's Ministry of Health, Labour and Welfare approved the company's enFuse On-Body Delivery System through Sanofi's CirCLIQ Injector. The device delivers a subcutaneous form of Sarclisa (isatuximab) with the push of a button, for treating multiple myeloma. It is the first anticancer treatment given through an on-body injector in Japan. The approval follows recent clearances in the US and Europe. Japan approved Sarclisa SC in June 2026, backed by the IRAKLIA phase 3 study, which showed the subcutaneous form was non-inferior to intravenous delivery. "We're proud to partner with Sanofi to bring our enFuse technology to patients in Japan," said Michael D. Hooven, chairman and chief executive officer of Enable.

Yahoo Finance
Oct 1st, 2026
Sanofi, Regeneron expand alliance in up to $8B deal for immunology drugs

France's Sanofi and US-based Regeneron Pharmaceuticals will expand their 20-year partnership to jointly develop and market immunology medicines in a deal worth up to $8 billion. Regeneron will receive $1 billion upfront, with potential additional payments of up to $7 billion tied to development, regulatory, and commercial targets. The collaboration will add four next-generation immunology drug candidates invented by Regeneron, with one currently in early-stage trials for eczema. The companies will equally share development costs and future profits from new drugs, whilst their existing profit-sharing agreement for top-selling medicine Dupixent remains unchanged. The deal settles prior litigation between the companies and marks an early move by Sanofi's new chief executive Belen Garijo to strengthen the company's pipeline.

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Vicebio

Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”). This acquisition brings an early-stage combination...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Blueprint Medicines

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes the acquisition of Dynavax

Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition...